<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089126</url>
  </required_header>
  <id_info>
    <org_study_id>LG-GGCL001</org_study_id>
    <nct_id>NCT02089126</nct_id>
  </id_info>
  <brief_title>Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to demonstrate the superiority and safety of the combination therapy&#xD;
      (as a fix-dose combination) with Gemigliptin and Glimepiride, compared to the Glimepiride&#xD;
      monotherapy in patients with type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c Changes</measure>
    <time_frame>Week 0, Week 24</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Gemigliptin/Glimepiride combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemigliptin 50mg qd added to ongoing Glimepiride as fix-dose combination. The subjects will take a total of 2 tablets, Gemigliptin/Glimepiride combination &amp; Placebo for Glimepiride.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The subjects will take a total of 2 tablets, Placebo for Gemigliptin/Glimepiride combination &amp; Glimepiride.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin/Glimepiride combination</intervention_name>
    <arm_group_label>Gemigliptin/Glimepiride combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with type 2 diabetes&#xD;
&#xD;
          2. Adults who are at least 19 years old&#xD;
&#xD;
          3. Patients who have taken Glimepiride at a stable dose (≥4mg/day) for 8 weeks or more&#xD;
             before Visit 1 (screening) as monotherapy or Patients who have taken Glimepiride at a&#xD;
             stable dose (≥4mg/day) and Metformin for 8 weeks or more before Visit 1 (screening) as&#xD;
             combination therapy&#xD;
&#xD;
          4. Patients who satisfy the following HbA1c (%) criteria: 7 ≤ HbA1c ≤ 11&#xD;
&#xD;
          5. Patients who have been provided an explanation about the objective, method, effects,&#xD;
             etc. of the clinical trial and whose informed consent form has been signed by&#xD;
             himself/herself or his/her representative&#xD;
&#xD;
          6. Patients who fall under one of the following 3 cases&#xD;
&#xD;
               1. Patients who are surgically sterile&#xD;
&#xD;
               2. Post-menopausal females who are above 45 years of age and 2 years after the last&#xD;
                  menstruation&#xD;
&#xD;
               3. Fertile premenopausal female patients or male patients without having a surgical&#xD;
                  sterilization, who have agreed to use at least two contraception methods (one of&#xD;
                  the barrier methods must be included) for up to 14 days after the administration&#xD;
                  of the last investigational product to avoid pregnancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with type 1 diabetes, diabetic ketoacidosis, diabetic coma and pre-coma&#xD;
&#xD;
          2. Patients with gestational diabetes or secondary diabetes&#xD;
&#xD;
          3. Patients with NYHA Class III, IV congestive heart failure or arrhythmias requiring&#xD;
             treatment&#xD;
&#xD;
          4. Patients with thyroid gland dysfunction and TSH that is out of normal range&#xD;
&#xD;
          5. Patients with pituitary insufficiency or adrenal insufficiency&#xD;
&#xD;
          6. Patients with hereditary problems, such as galactose intolerance, Lapp lactose&#xD;
             deficiency or glucose-galactose malabsorption&#xD;
&#xD;
          7. Female patients who are pregnant or breastfeeding&#xD;
&#xD;
          8. Patients whose BMI exceeds 40 kg/m2&#xD;
&#xD;
          9. Patients whose creatinine clearance is below 30mL/min/1.73m2&#xD;
&#xD;
         10. Patients whose bilirubin level exceeds 1.5 times the upper limit of the normal range&#xD;
             and whose ALT/AST level exceeds 2.5 times the upper limit of the normal range&#xD;
&#xD;
         11. Patients who are continuously taking the following drugs for 2 weeks or more at Visit&#xD;
             1 (screening), or need to take them continuously and repeatedly&#xD;
&#xD;
               -  cyclosporin, sirolimus, tacrolimus, nicotinic acid (≥1500mg/day), isotretinoin&#xD;
&#xD;
               -  Strong CYP3A4 inducers: rifampicin (rifampin), phenytoin, carbamazepine,&#xD;
                  rifabutin, phenobarbital&#xD;
&#xD;
               -  warfarin, dicoumarin, digoxin&#xD;
&#xD;
               -  systemic glucocorticoids&#xD;
&#xD;
         12. Patients who have taken anti-obesity drugs or had a surgery related to obesity within&#xD;
             12 weeks before Visit 1 (screening)&#xD;
&#xD;
         13. Patients who have received insulin and GLP-1 analogue treatment within 8 weeks prior&#xD;
             to Visit 1 (screening)&#xD;
&#xD;
         14. Patients who have received a treatment due to malignant tumor within 5years before&#xD;
             Visit 1 (screening) However, patients whose basal cell or squamous cell skin cancer or&#xD;
             in situ cervical cancer has been treated can be enrolled.&#xD;
&#xD;
         15. Patients with a history of myocardial infarction, unstable angina and coronary artery&#xD;
             bypass surgery within 6 months prior to Visit 1 (screening)&#xD;
&#xD;
         16. Patients with a history of alcohol or drug addiction within 1 year prior to Visit 1&#xD;
             (screening)&#xD;
&#xD;
         17. Patients who have a medical history of hypersensitivity to the same class as&#xD;
             Gemigliptin or dipeptidyl peptidase 4 (DPP 4) inhibitor drugs&#xD;
&#xD;
         18. Patients with a history of hypersensitivity to the drugs belonging to the same class&#xD;
             as Glimepiride or sulfonylureas and sulfonamide&#xD;
&#xD;
         19. Patients who have participated in another clinical trial within 3 months prior to&#xD;
             Visit 1 (screening)&#xD;
&#xD;
         20. Patients deemed unsuitable for this trial based on the judgment of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jong Hee Jin</last_name>
    <phone>82-2-6924-3122</phone>
    <email>jonghee@lgls.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Cha</last_name>
      <email>songppm@cmcnu.or.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 13, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <last_update_submitted>March 14, 2014</last_update_submitted>
  <last_update_submitted_qc>March 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

